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Abstract: A regional approach can protect our patients from often unacceptable adverse 
effects produced by systematically applied drugs. Regional therapeutic approaches, as well 
as interventions at the level of the peripheral nervous system and particularly the dorsal root 
ganglion (DRG), represent an alternative to the systemic application of therapeutic agents. 
This article provides an overview of DRG anatomical peculiarities, explains why the DRG is 
an important therapeutic target, and how animal models of targeted drug delivery can help us 
in the translation of basic research into clinical practice.
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Introduction
The best available evidence indicates a major gap between an increasing understanding 
of the pathophysiology of pain and the disappointing inadequacy of its treatment.1 
Unfortunately, physicians still rely on relatively ineffective analgesic drugs burdened 
with serious side effects. Meta-analyses of randomized clinical trials (RCTs) showed 
that only a few drugs are effective across the range of neuropathic pain disorders.2 
Moreover, a limited number of basic research discoveries have been translated from 
animal pain models into effective pain therapy.3,4 Therefore, the translation of basic 
scientific discoveries into practical, clinical applications is a priority, as well as an 
improvement of treatment protocols and adjunctive therapies that promote greater 
effectiveness, patient adherence, or patient tolerance.
We are all well aware of the often unacceptable adverse effects produced by cer-
tain drugs when applied systematically or through the central nervous system (CNS). 
The regional therapeutic approach and interventions at the level of the peripheral 
nervous system, and particularly the dorsal root ganglion (DRG), represent an alterna-
tive to the systemic application of therapeutic agents. Many diseases of the peripheral 
nervous system are local rather than systemic (eg, trauma, cancer, zoster, radiculopathy) 
so the therapeutic approach can also be regional. In this review we will discuss what is 
already known about DRG targeted drug delivery in animal models and why the DRG 
is an important therapeutic target. The aim of this review is to foster the translation of 
basic research into clinical practice.
Why the DRG is so special?
The DRG is located between the dorsal root and the spinal nerve. It contains 
pseudounipolar neurons that convey sensory information from the periphery to 
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the CNS. Following nerve injury or inflammation, these 
neurons may become an important source of increased 
  nociceptive   signaling through increased neuronal excitability 
and generation of ectopic discharges.5,6 This provides an 
excellent opportunity for the anesthesia of DRG neurons 
in order to prevent the development of these pathological 
discharges.
The DRG also lacks a protective surrounding capsular 
membrane, unlike the perineurium that protects the peripheral 
nerve fascicles and regulates their internal milieu.7 It has 
a permeable connective tissue capsule, which makes it an 
excellent choice for drug application.7 This permeability 
can be partly explained by a very high density of blood 
capillaries in the ganglion tissue.8 This rich blood supply may 
also explain why the DRG is tolerant to the intraneuronal 
local anesthetic injection, since toxic concentration cannot 
be easily reached due to high perfusion rates.9
As opposed to the blood–brain barrier in the CNS, the 
DRG and peripheral axons lack an efficient neurovascular 
barrier, which allows the easy diffusion of large molecular 
weight compounds in the interstitium surrounding the DRG 
neurons.7 This absence of a vascular barrier exposes DRG 
neurons to toxic circulating agents, like intravenously applied 
antineoplastic drugs and antiretroviral agents, which thereby 
produce treatment-limiting peripheral neuropathy that is 
selective for sensory neurons in the DRG.10 The special 
position of the DRG also exposes them to injury. A close 
juxtaposition of sensitive neuronal and sturdy bone   structures 
is probably the main reason for DRG injury (Figures 1 and 2). 
Arthritis of the zygapophyseal (facet) joint and the herniation 
of the intervertebral disc are the most common causes of 
radiculopathy.11 The chronic compression of the DRG or 
nearby nerve roots after vertebral injuries, intervertebral disc 
herniation, or intervertebral foramen stenosis is an impor-
tant factor causing lower back pain and sciatica. In 1998 a 
method of producing chronic compression of the L5 DRG 
in rats was described, with expectations that this animal 
model will increase our understanding of lower back pain 
and sciatica.12 Peripheral or nerve root injury due to bone 
injury induces the synthesis and the release of numerous 
inflammatory   mediators that can sensitize nociceptors and 
enhance pain.13,14
Initial pathological changes  
in the DRG are the main triggers 
for neuropathic pain
The most important changes responsible for the induction 
of neuropathic pain are found in the altered gene/protein 
expression in primary sensory neurons. After damage to 
peripheral sensory fibers, upregulated expression of the 
Cavα2δ-1 channel subunit, the Nav1.3 sodium channel, and 
bradykinin (BK) B1 and capsaicin TRPV1 receptors in 
myelinated neurons contribute to hyperalgesia; while the 
downregulation of the Nav1.8 sodium channel, B2 receptor, 
substance P (SP), and even µ-opioid receptors in unmyeli-
nated neurons is responsible for the phenotypic switch in 
pain transmission.15
Many studies have focused on finding the source of abnor-
mal spontaneous activity within DRG neurons. Voltage-gated 
sodium channels, which are essential for the generation and 
conduction of action potentials, are potential targets for 
treating neuropathic pain. Changes in their density, distribu-
tion, and functional activities following nerve injury were 
extensively studied. However, preclinical studies have shown 
unexpected results because most pain-associated voltage-
gated channels in the DRG are downregulated after peripheral 
nerve injury. The possible role of the DRG voltage-gated 
sodium channel function in neuropathic pain remains to be 
further investigated.16
Neurons are not the only players that drive the estab-
lishment and maintenance of common clinical pain states. 
Figure 1 The position of the rat L5 DRG and its relation with surrounding bone 
structures and cauda equina. 
Abbreviations:  DRG,  dorsal  root  ganglion;  DR,  dorsal  root;  CE,  cauda  equina;   
P, pedicles.
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It is now clear that immune and glial cell responses alter 
neuronal function in the peripheral and central nervous 
system.17   Neurons in the DRG are surrounded by an enve-
lope of satellite glial cells (SGCs), which carry receptors 
for numerous neuroactive agents and can therefore receive 
signals from other cells and respond to changes in their 
environment (Figure 3). Activation of SGCs might in turn 
influence neighboring neurons, and thus SGCs may par-
ticipate in signal processing and transmission in sensory 
ganglia. Damage to the axons of sensory ganglia contrib-
utes to neuropathic pain. Such damage also affects SGCs 
so these cells have a role in the pathological changes in 
the ganglia.18
A major determinant of neuronal excitability is the 
extracellular concentration of potassium, which is   regulated 
primarily by ion channels expressed by the SGCs that 
  surround primary sensory neurons.18 Indeed, it has been 
shown that the impairment of glial potassium homeostasis in 
the sensory ganglia contributes to pain patomechanisms.19
After peripheral axotomy, there is an increased expres-
sion of neurotrophic factors such as nerve growth factor 
(NGF) and neurotrophin-3 (NT3) in satellite cells surround-
ing sensory neuron cell bodies in the DRG. These neu-
rotrophins within the DRG trigger a persistent mechanical 
allodynia, showing that ganglia-derived neurotrophins are 
a source of nociceptive stimuli for neuropathic pain after 
peripheral nerve injury.20 This change may be sufficient to 
trigger the sprouting of sympathetic fibers within the DRG 
after peripheral nerve injury and in this way contribute to 
  neuropathic pain.21
In a 2011 report, Li et al have shown that a single injec-
tion of corticosteroid in the vicinity of axotomized DRG can 
mimic many effects of systemic corticosteroid administra-
tion, mitigating behavioral and cellular abnormalities induced 
by spinal nerve ligation. Specifically, this treatment attenu-
ated mechanical sensitivity, reduced sympathetic sprouting in 
the DRG, and decreased satellite glia activation in the DRG 
and microglia activation in the spinal cord after SNL. These 
findings provide further support for the idea that localized 
inflammation at the level of the DRG is an important com-
ponent in neuropathic pain development.22
Figure 2 Schematic drawings (A and B) and photo (C) of rat spine depicting 
position of dorsal root ganglia and surgical approach used for DRG injection.36 
Reliably precise injection can be performed using minimal laminectomy, while blind 
needle-insertion approach requires a lot of skill and experience. The dorsal root 
ganglion is covered by laminar bone. (B) Removal of laminar bone superior to 
the foramen and the L4 accessory process reveals the distal dorsal root ganglion, 
recognized by its broader diameter. 
Abbreviations: red arrows, dorsal root ganglion (L5 and L6); sap, superior articular 
processes; sp, spinous processes; tp, transverse processes; lam, laminar bone.
Figure 3 Microphotograph of dorsal root ganglion obtained from frozen section 
showing juxtaposition of DRG neurons and satellite cells. 
Abbreviations: SC, satellite cells; N, neurons; Nu, nucleolus; Bv, blood vessels; 
NC, nucleus; CT, connective tissue.
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DRG delivery in studies of pain 
mechanisms
Different agents have been applied into the DRG in studies 
investigating pain mechanisms. In 1991, Lu and Richardson 
published a study in which an inflammatory reaction was pro-
voked in rat DRG through the injection of Corynebacterium 
parvum and isogenous macrophages into the ganglion. The 
study concluded that changes favorable to axonal regen-
eration can be induced by products of inflammatory cells 
acting in the vicinity of the nerve cell body, and gave an 
indirect support to the idea that non-neuronal cells in the 
DRG might influence regenerative responses of primary 
sensory neurons.23
In an experimental model for chronic compression of the 
DRG a Ca2+ chelator and K+ channel blocker were topically 
applied to the DRG to determine whether the effects on 
neuronal response differ for normal and chronically injured 
DRG neurons.12
DRG injection of isolectin B4 from Griffonia simplicifolia 
I (B4) conjugated to horseradish peroxidase (HRP) revealed 
that B4-HRP should be a suitable anterograde tracer of unmy-
elinated cutaneous and splanchnic but not muscle primary 
afferent fibers.24
Exposing rat DRG neurons to dibutyryl cAMP (db-cAMP) 
enables central branches to regenerate in the spinal cord by 
nullifying the ability of central nervous system myelin to 
inhibit elongation. It has been demonstrated that the intra-
ganglionic injection of db-cAMP increases the expression 
of growth-associated tubulin isotypes, thus contributing to 
changes that may be necessary in order to increase intrinsic 
axon growth capacity.25 Further studies with intra-DRG 
injection of db-cAMP suggested that the beneficial actions 
of increased cyclic AMP activity on axonal regeneration of 
primary sensory neurons are mediated, at least in part, by 
the induction of neuropoietic cytokine synthesis within the 
dorsal root ganglion.26
DRG injection of a potent and selective TRPV1 receptor 
antagonist has helped in explaining how noxious thermal 
stimulation triggers the transmission of TRPV1-related 
signals to spinal wide dynamic range neurons in rats with 
peripheral inflammation.27
Our study of the role of neuropeptide Y (NPY) in pain 
modulation included the injection of NPY and its specific 
Y1 and Y2 receptor antagonists directly into the DRG. 
The   exacerbation of pain-related behavior following NPY 
injection was accompanied by astrocyte activation in 
ipsilateral dorsal horn and with satellite cells activation in 
the DRG proximal to injury. This activation was reduced 
following Y2 receptor antagonist application. These findings 
indicate an important link between pain-related behavior and 
neuroimmune activation by NPY through its Y2 receptor.28
Targeting DRG for studying existing 
and novel therapies
To investigate the neurologic mechanisms of acidic local 
anesthetic-induced lower back pain in humans, Zhang et al 
administered bupivacaine and buffered saline at acidic or 
alkalinized pH at the L5 DRG of rats. The results demon-
strated that acidic bupivacaine deposited at the DRG causes 
pain and hyperalgesia following the dissipation of local 
anesthetic effects. These findings may explain the limited 
therapeutic effects of some acidic local anesthetics used for 
the management of cancer-related and chronic back pain.29
A study of the selective migration and engraftment of 
bone marrow mesenchymal stem cells (MSCs) injected in 
rat lumbar DRG after sciatic nerve constriction showed the 
possible use of MSCs as a new therapeutic strategy for the 
treatment of peripheral nerve neuropathies.30
In the past decade we have witnessed the development of 
gene therapy for pain in the DRG. The targeted expression 
of foreign genes to the peripheral nerve system is interesting 
for many applications, including gene therapy of neuromus-
cular diseases, neuroanatomical studies, and elucidation of 
mechanisms of axonal flow. In 2000, Glatzel et al described 
a microneurosurgical technique for the injection of viral vec-
tors into DRG. Vectors with transcriptional competence for 
DRG neurons led to the expression of the gene of interest. 
This study showed that DRG injection was vastly superior 
to the intraneural injection into the sciatic nerve.31
Fischer et al showed that the use of the DRG approach for 
the anatomically selective administration of a viral vector is 
associated with genetic modification of sensory neurons in the 
segment of the injected DRG, thus confirming the utility of the 
technique for research on sensory mechanisms and the pos-
sibility of therapeutic translation for the treatment of chronic 
pain.32 Yu et al showed the potential of lentivectors as a viable 
system for delivering target genes into DRGs to explore basic 
mechanisms of neuropathic pain, with the potential for future 
clinical use in the treatment of chronic pain.33
An interesting alternative to direct DRG gene therapy 
has recently been described. In 2008, Liu et al reported that 
subcutaneous inoculation of a novel human foamy virus 
(HFV) vector may be used to transfer the glutamic acid 
decarboxylase (GAD) gene to DRG cells to attenuate below-
injury level central neuropathic pain after spinal cord injury.34 
Terashima et al genetically modified an adenovirus (Ad) to 
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generate a helper virus (HV) that was detargeted for native 
adenoviral tropism and contained DRG homing peptides in 
the adenoviral capsid fiber protein. They used this HV to 
generate DRG-targeted helper-dependent Ad (HDAd). In 
mice, intrathecal injection of this HDAd produced a 100-
fold higher transduction of DRG neurons and a markedly 
attenuated inflammatory response compared with unmodified 
HDAd. This therapy showed promising results in an animal 
model of neuronopathy.35
Experimental models  
for DRG injection
However, targeted DRG delivery in small animal subjects is 
a methodological challenge, as DRGs are enclosed within the 
intervertebral foramen and are therefore not easily accessible 
for intraganglionic injection (Figure 2).36
Our group compared three methods of targeted DRG 
delivery, including percutaneous injection, intraganglionic 
injection after soft tissue removal and advancement of the 
needle into intervertebral foramen, and intraganglionic 
injection after laminar bone removal and exposure of the 
caudal pole of the DRG.36 Our results showed that intra-
ganglionic injection after partial laminectomy resulted in a 
consistently successful injection into the DRG, as validated 
both with Coomassie blue and Fast Blue dyes. The removal 
of soft tissue but no bone, with blind insertion of the needle 
through the intervertebral foramen, is more challenging 
and less   successful. Although it may take longer to achieve 
consistently successful results, the less traumatic approach 
of leaving the bone intact may have an advantage in creating 
less trauma and inflammation (Figure 2).36
Our analysis of the literature revealed that substantial 
methodological diversity characterizes published reports of 
DRG injection, probably due to difficulties faced by investi-
gators when trying to access this structure. We also found that 
very few studies mention validation of DRG injections.36
In 2011, a technique for selective administration of an 
injected agent to a single DRG was further elaborated by 
Fischer et al. These findings indicate that direct injection of 
2 µL fills the adult rat DRG with only minor spread of the 
injectate to adjacent structures, produces minimal evidence 
of inflammatory changes, and has only mild and transient 
effects on sensory and motor function.32
The multitude of alternative techniques for intragan-
glionic injection has probably evolved to achieve specific 
experimental needs, but it may also be an indicator of a 
general inadequacy of the various methods. Our observation 
of the variability in results using approaches in which the 
DRG is not exposed indicates that anatomic validation should 
be an obligatory component of research reports describing 
experiments using DRG injection.36
Is DRG injection harmful?
Whereas the histopathological and behavioral changes 
following peripheral nerve injury due to direct injection have 
been well investigated, little is known about the consequences 
of injection within the DRG or the adjacent spinal nerve. 
Potential clinical application requires a safe procedure that 
avoids inflammation or pain-related behavior.
Our group evaluated the neuroinflammatory response 
following a lidocaine or saline injection into the DRG or the 
adjacent spinal nerve.37 We hypothesized that an inflamma-
tory response may follow local anesthetic injection into the 
DRG and produce hyperalgesia. In the experimental setting it 
has been reported that topical application of local anesthetic 
to the DRG induces mechanical hyperalgesia in the rat,29 but 
possible morphological changes in the DRG have not been 
studied. We have found that the injection of lidocaine into 
a DRG induced pain-related behavior and a marked inflam-
matory response in the DRG.37 It is important that we also 
identified an inflammatory response in saline-injected rats, 
but this was not accompanied with marked hyperalgesia, 
perhaps because this inflammatory response was significantly 
lower than after the lidocaine injection suggesting that DRG 
injection can be a secure procedure.37
Our findings raise the possibility that hyperalgesia after 
injection into the DRG may be attributed to an inflammatory 
response.37 The inflammation was evaluated through the acti-
vation of satellite and glial cells. The activation of these cells 
was evaluated through the expression of glial fibrillary acidic 
protein (GFAP). The activation of satellite cells is not specific 
for neuroinflammation, however, the lack of other possible 
reasons for its activation can help us attribute this activation 
to inflammatory processes. The activation was exhibited as 
rings of immunopositive satellite cells around neurons. Other 
markers of inflammation, like OX-42 immunopositive cells, 
which represent activated microglia, or Pan-T positive cells, 
which indicate activated T lymphocytes, were not observed 
in saline injected rats.37 These findings indicate that lidocaine 
injection into the DRG activates resident immunological 
cells, but it does not produce significant immigration of 
nonresident inflammatory cells into the DRG.
In addition to the inflammatory response, it is important 
to validate the behavioral consequences of DRG injection 
and to test behavioral responses following these procedures. 
We have demonstrated already that targeted drug delivery 
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by direct intraganglionar injection per se does not produce 
behavioral changes in rats.36
Recently we have also shown that small differences 
in surgical approach can result in significant behavioral 
  differences.38 Specifically, we investigated whether there 
is a direct relationship between the extent of laminectomy 
and the development of mechanical hypersensitivity after 
ganglionectomy. We found hyperalgesia in rats with exten-
sive laminectomy, regardless of performance or absence of 
ganglionectomy, while in rats with minimal laminectomy 
there was no increase in pain-related behavior.38
Based on these results it could be inferred that partial 
laminectomy is a rather precise method of injecting DRG 
and does not produce measurable behavioral differences. The 
observed variability in results using approaches in which the 
DRG was not exposed indicates that anatomic validation should 
be a part of the experimental procedure using DRG injection.
Limitations in ganglion approach
A limitation for DRG delivery is the location of the ganglion, 
which makes it difficult to reach. DRGs are protected by the 
bony structures of the vertebra. To reach DRGs in animal 
models, one needs to drill a hole in the bone covering the 
ganglion. In humans, due to larger structures, it is possible 
to access most of the DRGs via intervertebral foramen by 
carefully positioning a patient and navigating a needle using 
radiographic or ultrasound imaging, as shown by several 
approaches already used in a clinical setting. Pulsed radiofre-
quency (RF) of DRGs is a therapeutic procedure during which 
a heat lesion is placed sufficiently near the DRG to produce 
what is called a partial lesion, but not so close as to completely 
destroy the ganglion.39 Selective nerve root blocks (SNRBs) 
have been used for many years as a diagnostic tool in patients 
with lower back pain with radicular symptoms, as well as for 
pain relief. This technique also involves structures beyond 
the intervertebral foramen. However, patient responses to 
SNRBs are often non specific and pain relief after injecting 
local anesthetic is often difficult to interpret.40
The DRG can be injured during SNRBs.9 However, these 
injections into the DRG are well tolerated. The cervical level 
is a very important exception since there is a very short length 
from the DRG to the spinal cord, where arrival of the injected 
drug may produce disastrous cord damage.11
Alternatives to DRG targeted 
delivery of drugs
The idea to target specific parts of the nervous system in order 
to deliver therapeutics is not new, as shown by the principles 
of regional anesthesia. Within anesthetic practice, the role 
of regional anesthesia – including peripheral nerve block – 
has expanded greatly over the past two decades. In 1998, a 
national survey demonstrated that 88% of US anesthesiolo-
gists make use of regional techniques.41
Regional nerve blockade, or more commonly nerve block, 
is a general term used to refer to the injection of a local anes-
thetic onto or near the nerves for temporary control of pain. The 
idea of Johannes P Mueller (1801–1858) that nerves determine 
what the mind perceives sparked interest in nerve function.42 
By 1845, Sir Frances Rynd (1801–1861) had already delivered 
a morphine solution to a nerve in an effort to relieve intractable 
neuralgia, which appears to be the first documented nerve 
block as it is defined today.43 However, Rynd used a cannula 
to deliver a solution by means of gravity. Ten years later, in 
1855, Alexander Wood (1817–1884) used a graduated glass 
syringe and needle to perform the same procedure.44
Single-shot peripheral nerve blocks are mostly used for a 
variety of surgical procedures. A continuous peripheral nerve 
block, also termed “perineural local anesthetic infusion,” 
involves the percutaneous insertion of a catheter adjacent to 
a peripheral nerve, followed by local anesthetic administra-
tion via the catheter, providing anesthesia for multiple days 
or even months.45
Complications of peripheral nerve blocks include easily 
rectified minor complications that occur frequently, but major 
risks include nerve injury, catheter infection, bleeding, and 
local anesthetic systemic toxicity (LAST).46
Steroids may be given with or without anesthetics during 
peripheral nerve blocks. The clinical introduction of cortisone 
in 1949 revolutionized medical care for patients with various 
diseases. The first neuroaxial application of steroids in epi-
dural injections was already described in 1952. A variety of 
corticosteroid agents have been applied neuroaxially to treat 
spinal pain and other types of painful conditions, since it has 
been postulated that corticosteroids reduce inflammation by 
inhibiting either the synthesis or the release of a number of 
pro-inflammatory substances as well as by causing a revers-
ible local anesthetic effect.47
The perineural approach has also been described for 
other drugs, such as the introduction of the local injection 
perineural therapy of ipidacrinum for focal neuropathies of 
upper extremities, which exhibited significantly better results 
compared to intramuscular injections of the same drug.48
However, it should be noted that ectopic nerve activity 
occurs at the dorsal root ganglion and that is why peripheral 
nerve block may fail and perineural drug infusion may be 
ineffective for neuropathic pain treatment.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
36
Sapunar et alJournal of Pain Research 2012:5
Sympathetic block is also a well-known treatment in 
clinical practice. However, although there is a widely held 
view that sympathetic nerve blocks reduce incidence of pain 
in acute herpes zoster and postherpetic neuralgia, a critical 
review of the literature found little support for this notion.49
Epidural pathway is another option for targeted drug 
delivery. Epidural steroid injections have been used for 
more than 50 years to treat lower back pain and they are 
the most common intervention in pain clinics throughout 
the world.50
About a third of chronic lower back pain patients have 
predominantly neuropathic pain.51 However, in 2011, Iversen 
and colleagues reported the outcomes of a multicenter ran-
domized controlled trial, in which they concluded that caudal 
epidural steroids are not recommended for chronic lumbar 
radiculopathy.52
Intrathecal drug delivery is another interventional mode 
of pain treatment. However, most reported benefits of sys-
temic and regional analgesics and interventional approaches 
to pain relief are not based on randomized trials and are sub-
ject to selection bias, sampling error, and placebo responses, 
which may over-inflate reported benefits. Randomized con-
trolled trials are needed to confirm reported benefits.53 While 
intrathecal injection is a simple and relatively noninvasive 
means to deliver agents to sensory neurons, it is not possible 
to restrict the injected solution to a single side or to a limited 
longitudinal range of vertebral levels.32
Although multiple types of targeted interventional thera-
pies have been used in practice, needle trauma associated 
with these treatments may cause neuropathic pain itself.54,55 
Therefore, exploring new options for interventional pain 
management of neuropathic pain could be potentially useful 
for clinical practice.
Conclusion
The animal model for DRG targeted delivery of drugs is a 
valuable tool in pain research. Such an approach may pro-
vide adequate specificity to capitalize on the new knowledge 
of peripheral sensory nerve function in painful conditions. 
The development of new techniques for sustained infusions 
at the level of a single DRG and gene delivery using viral 
vectors are probable new venues for the regional therapeutic 
approach at the level of a single DRG.
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